News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|August 15, 2022

Motivational Interviewing: Partnering With Patients

Author(s)Brian Hurley, MD, MBA, DFASAM

Here's how to listen to patients and offer selective reflections.

Brian Hurley, MD, MBA, DFASAM, gives a summary on his talk on motivational interviewing from the 2022 Annual Psychiatric Times™ World CME Conference.

Dr Hurley is the Medical Director of the Substance Abuse Prevention and Control at the Los Angeles County Department of Public Health.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

XPro1595 Alzheimer disease inflammation

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

ByJessica Walters

December 3rd 2025

Patient Awareness of Tardive Dyskinesia: Insights From Cherian Karunapuzha, MD

ByCherian Karunapuzha, MD

December 3rd 2025

David Medina

Managing Treatment-Resistant Depression: Insights From David Medina, MD, FAPA

ByDavid Medina, MD, FAPA

December 2nd 2025

Manish Zinzuvadia, MD

Challenges in Bipolar Disorder: Discussion With Manish Zinzuvadia, MD

ByManish Zinzuvadia, MD

December 2nd 2025

postpartum depression

"Words Matter": Best Practices in Treating Postpartum Depression

ByErin Crown, MHS, PA-C, Psych-CAQ

December 1st 2025

Latest CME

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

The Concept of Mental Illness, and Why the DSM Approach Is Wrong

Okie Tokie Talk: Adolescent Cannabis Use in Oklahoma, the Sooner State

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Data Presentation on XPro1595 for Alzheimer Disease With Inflammation at CTAD

Delay on Cobenfy Alzheimer Disease Psychosis Data Following Phase 3 Study “Irregularities,” New Patients Enrolled

© 2025 MJH Life Sciences^®

All rights reserved.